A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs IMO 8400 (Primary)
  • Indications Dermatomyositis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2017 According to an Idera Pharmaceuticals media release, this trial is being conducted at 22 sites both in the U.S. and abroad.
    • 28 Oct 2016 According to an Idera Pharmaceuticals media release, company anticipates clinical data available in early 2018.
    • 02 Aug 2016 According to an Idera Pharmaceuticals media release, the company plans to complete enrollment of this trial by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top